Dopamine D2 receptor antagonist - Pipeline Insight, 2024

Dopamine D2 receptor antagonist - Pipeline Insight, 2024

DelveInsight’s, “Dopamine D2 receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dopamine D2 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dopamine D2 receptor antagonists Understanding

Dopamine D2 receptor antagonists: Overview

DRD2 encodes the D2 subtype of the dopamine receptor that inhibits adenylyl cyclase activity. Alternative splicing of this G protein-coupled receptor results in two transcript variants encoding different isoforms. DRD2 plays a major role in the neural circuitry that mediates behavioral control, an ability that is essential for adaptive responding and is compromised in a variety of common neuropsychiatric disorders.

Function – Dopamine receptors are G protein–coupled receptors involved in the regulation of motor activity and several neurological disorders such as schizophrenia, bipolar disorder, Parkinson’s disease (PD), Alzheimer’s disease, and attention-deficit/hyperactivity disorder. Dopamine is a monoamine catecholamine neurotransmitter belonging to the 7 transmembrane G protein–coupled receptors (GPCRs), which play an important role in the regulation of not only motor functions but also non-motor functions such as motivation, cognition, emotion, and neuroendocrine secretion.

Dopamine D2 receptor antagonists- Dopamine (DA) D2 receptor antagonists have been linked to elevated levels of nicotine dependence in smokers with schizophrenia. Because activation of D2 receptors mediates motivation for nicotine, potent D2 antagonists would diminish nicotine's ability to stimulate reward processing-a mechanism that may drive compensatory increases in smoking.

Dopamine D2 receptor antagonists Emerging Drugs Chapters

This segment of the Dopamine D2 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dopamine D2 receptor antagonists Emerging Drugs

• Pridopidine: Prilenia Therapeutics

Pridopidine is an oral drug currently in development for the treatment of Huntington’s disease and ALS. It is administered in a small easy-to-swallow capsule twice a day. Pridopidine is being evaluated in Phase III stage of development for the treatment of patients with Huntington's disease.

• FKF 02SC: Fabre-Kramer Pharmaceuticals

FKF 02SC is a potent dopamine D2 receptor antagonist being developed by Fabre-Kramer Pharmaceuticals. The drug is currently in Phase II stage of development for the treatment of patients with Schizophrenia.

Further product details are provided in the report……..

Dopamine D2 receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Dopamine D2 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Dopamine D2 receptor antagonists

There are approx. 10+ key companies which are developing the Dopamine D2 receptor antagonists. The companies which have their Dopamine D2 receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Prilenia Therapeutics

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Dopamine D2 receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dopamine D2 receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine D2 receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine D2 receptor antagonists drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine D2 receptor antagonists R&D. The therapies under development are focused on novel approaches for Dopamine D2 receptor antagonists.

Dopamine D2 receptor antagonists Report Insights

• Dopamine D2 receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dopamine D2 receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Dopamine D2 receptor antagonists drugs?
• How many Dopamine D2 receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Dopamine D2 receptor antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine D2 receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dopamine D2 receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?